Loading...
XNASORGS
Market cap9mUSD
Dec 31, Last price  
1.89USD
1D
-10.43%
1Q
-57.24%
Jan 2017
-39.05%
IPO
-72.61%
Name

Orgenesis Inc

Chart & Performance

D1W1MN
XNAS:ORGS chart
P/E
—
P/S
18.43
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.75%
Rev. gr., 5y
-50.94%
Revenues
530k
-98.53%
00000002,974,0006,397,00010,089,00018,655,00033,256,0007,652,00035,502,00036,025,000530,000
Net income
-55m
L+354.93%
-3,500-25,648-36,173-72,352-4,998,143-5,539,159-5,504,101-4,461,000-9,194,000-12,367,000-18,291,000-26,041,000-95,127,000-18,059,000-12,169,000-55,361,000
CFO
-15m
L-40.47%
0-23,576-14,960-189-1,051,612-1,989,348-1,429,247-2,706,000-3,783,000-3,833,000-15,682,000-13,220,000-78,046,000-26,866,000-24,924,000-14,837,000
Earnings
May 19, 2025

Profile

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
URL
https://www.orgenesis.com/
IPO date
Jul 01, 2010
Employees
167
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑112017‑122016‑112015‑11
Income
Revenues
530
-98.53%
36,025
1.47%
Cost of revenue
52,430
42,039
Unusual Expense (Income)
NOPBT
(51,900)
(6,014)
NOPBT Margin
Operating Taxes
473
209
Tax Rate
NOPAT
(52,373)
(6,223)
Net income
(55,361)
354.93%
(12,169)
-32.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,283
2,181
BB yield
-3.64%
-0.45%
Debt
Debt current
3,554
5,106
Long-term debt
19,401
17,591
Deferred revenue
144
Other long-term liabilities
61
434
Net debt
22,110
17,251
Cash flow
Cash from operating activities
(14,837)
(24,924)
CAPEX
(2,096)
(12,416)
Cash from investing activities
(3,707)
(14,133)
Cash from financing activities
13,618
19,578
FCF
12,825
(42,620)
Balance
Cash
837
5,311
Long term investments
8
135
Excess cash
818
3,645
Stockholders' equity
(176,554)
(89,815)
Invested Capital
178,253
169,650
ROIC
ROCE
EV
Common stock shares outstanding
29,008
25,096
Price
5.01
-74.32%
19.50
-32.29%
Market cap
145,242
-70.32%
489,378
-30.00%
EV
167,352
538,342
EBITDA
(50,340)
(4,036)
EV/EBITDA
Interest
2,167
1,824
Interest/NOPBT